Skip to main content

Table 1 Patient characteristics of both marker discovery and validation studies

From: DNA methylation epigenotypes in breast cancer molecular subtypes

   Type
   Basal ERBB2+ Luminal B Luminal A
Number of patients   59 49 54 53
Age (years)      
  Mean 56.1 57.1 56.9 62.9
  Median 53 57.5 51 61
  Range (95% CI) 51.5-60.7 52.5-61.6 51.8-61.7 56.9-68.7
Tumor size (cm)      
  Mean 2.4 2.8 3.2 3.1
  Range (95% CI) 2.1-2.7 2.1-3.5 2.5-3.5 2.4-3.7
Histologic grade (%)      
  I 5.0 0.0 0.0 6.0
  II 47.1 24 40.0 55.5
  III 48.9 76 60.0 38.5
Nodal involvement (%)      
  Positive 35.5 63.4 72.2 57.3
  Negative 64.4 36.6 27.8 42.7
Ki-67 overexpression (%)      
  <10% 0.0 8.9 21.9 27.8
  10%-25% 0.0 36.1 31.2 66.7
  >25% 100.0 56.0 46.9 5.6
p53 mutation (%)      
  Positive 47.2 44.1 21.8 14.8
  Negative 52.8 55.9 88.2 85.2